New Delhi, March 30 -- Top medical experts are raising urgent alarms against using GLP-1 as a lifestyle enhancer, highlighting the risk of shortages for high-risk patients.

GLP-1 receptor agonists like Ozempic, Wegovy, and Mounjaro are powerful prescription medicines designed for long-term management of chronic conditions like obesity and type 2 diabetes. They're not a quick fix for weight loss or a substitute for healthy lifestyle changes.

Multiple domestic pharmaceuticals has launched Semaglutide after the patent expired in India, but since the launch of Semaglutide its massively promoted, it has created risk factors for actual beneficiaries.

Speaking to ANI, Dr Saptarshi Bhattacharya, Senior Consultant Endocrinology, Indraprastha Ap...